Compass is listed as collaborator on an investigator-initiated study at UC San Diego, to explore the safety, tolerability, & efficacy of psilocybin-assisted therapy for anorexia
Another study, sponsored by Imperial College London, will also assess the acceptability & efficacy of treating anorexia with psilocybin, & will use MRI & EEG to examine neuronal underpinnings of tx
A primary difference between the new ‘257 & the first ‘175 patent is:
– ‘175 patent claims methods “of treating drug resistant depression” by orally administering “an oral dosage form“ of the COMP360 psilocybin Polymorph A
– ‘257 patent claims the “oral dosage form” itself
2/7
Just as with the first ‘175 patent, the new ‘257 patent claims the psilocybin Polymorph A by reference to its “XRPD diffractogram”
These are the peaks displayed when the polymorph is analyzed by X-ray
Compass unsuccessfully sought claims without these XRPD limitations
Application claims compositions of “psilocybe-derived agent and a cannabis-derived agent”
”formulated in multiple layers to release the psilocybin-derived agent and the cannabis-derived agent at multiple different times, dosages and/or locations in a subject during dosing”
2/
Application asserts controlled release formulations of psilocybin + CBD can result in “multiple chemical-induced high/low shocks”
"useful in eliciting short or long term traumatic experience suppression in similar fashion to electroshock therapy without memory eradication”
US Patent No. 10,870,632 “Process For Producing An Extract Containing Tetrahydrocannabinol And Cannabidiol From Cannabis Plant Material, And Cannabis Extracts”
New patent application by Small Pharma published today.
The “invention provides compositions and methods which enable a finely tuned single dose to maintain a patient in full dissociation from the external world, referred to herein as ‘DMT space.’”
1/
In particular, the invention takes advantage of “the kinetic isotope effect” exhibited by deuterated DMT analogs “in order to modify, controllably, the pharmacokinetic profile of N,N-DMT, thereby permitting more flexible therapeutic application.”
“Deuterated” means that one or more hydrogen atoms in DMT are replaced by its heavier stable isotope deuterium. Because of the “kinetic isotope effect,” deuterated drugs may have significantly lower rates of metabolism and a longer half-life.